INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $170.06 million. The enterprise value is $138.54 million.

Market Cap	170.06M
Enterprise Value	138.54M

Important Dates

The last earnings date was Thursday, October 31, 2024, after market close.

Earnings Date	Oct 31, 2024
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 22.17 million shares outstanding. The number of shares has increased by 5.16% in one year.

Current Share Class	22.17M
Shares Outstanding	22.17M
Shares Change (YoY)	+5.16%
Shares Change (QoQ)	+4.55%
Owned by Insiders (%)	20.40%
Owned by Institutions (%)	24.72%
Float	14.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.74
P/TBV Ratio	7.63
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	3,298.50
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.59, with a Debt / Equity ratio of 0.08.

Current Ratio	2.59
Quick Ratio	2.53
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-23.93

Financial Efficiency

Return on equity (ROE) is -98.97% and return on invested capital (ROIC) is -52.34%.

Return on Equity (ROE)	-98.97%
Return on Assets (ROA)	-44.97%
Return on Capital (ROIC)	-52.34%
Revenue Per Employee	$2,471
Profits Per Employee	-$2.43M
Employee Count	17
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.72% in the last 52 weeks. The beta is 1.79, so INmune Bio's price volatility has been higher than the market average.

Beta (5Y)	1.79
52-Week Price Change	-32.72%
50-Day Moving Average	5.28
200-Day Moving Average	7.22
Relative Strength Index (RSI)	72.88
Average Volume (20 Days)	399,570

Short Selling Information

The latest short interest is 4.28 million, so 19.30% of the outstanding shares have been sold short.

Short Interest	4.28M
Short Previous Month	4.00M
Short % of Shares Out	19.30%
Short % of Float	30.20%
Short Ratio (days to cover)	18.51

Income Statement

In the last 12 months, INmune Bio had revenue of $42,000 and -$41.27 million in losses. Loss per share was -$2.19.

Revenue	42,000
Gross Profit	42,000
Operating Income	-41.55M
Pretax Income	-37.74M
Net Income	-41.27M
EBITDA	n/a
EBIT	-41.55M
Loss Per Share	-$2.19

Full Income Statement

Balance Sheet

The company has $33.55 million in cash and $2.91 million in debt, giving a net cash position of $30.64 million or $1.38 per share.

Cash & Cash Equivalents	33.55M
Total Debt	2.91M
Net Cash	30.64M
Net Cash Per Share	$1.38
Equity (Book Value)	38.68M
Book Value Per Share	1.74
Working Capital	22.03M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-25.75M
Capital Expenditures	n/a
Free Cash Flow	-25.75M
FCF Per Share	-$1.16

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-98,921.43%
Pretax Margin	-98,266.67%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.16%
Shareholder Yield	-5.16%
Earnings Yield	-24.40%
FCF Yield	-15.22%

Analyst Forecast

The average price target for INmune Bio is $21.00, which is 173.79% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$21.00
Price Target Difference	173.79%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	224.16%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of 1.26 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.26
Piotroski F-Score	1